An incredible experience presenting our work at #ASH24! Truly grateful for the guidance and support from the best mentor @NicholasShortMD.

👉👉👉We are super proud to welcome our newest class of Heme/Onc Fellow MDs to @MDAndersonNews !!! 📣 Congratulations! @KellyMezaMD @HannahGoulart @JenMarvinPeek @lungoncdoc @VanMorrisMD @homesforhealers @marklewismd @Daver_Leukemia @mtmdphd | #MatchDay #Fellowship #meded

A dream come true. Absolutely thrilled to have matched at @MDAndersonNews for heme/onc fellowship. Grateful for my incredible support system, the mentors who shaped my path, and my training at @BCM_InternalMed. #FellowMatch

Our team won the @SocietyofHemOnc Honorable Distinction award for our poster submission on the prognostic impact of NGS MRD in Ph- ALL! Special thanks to @NicholasShortMD @WNMacaron @DrHKantarjian

Survival of adult #ALL is significantly better 👍 ‼️ Ph ➖ ALL: Adding antibodies & immunotherapy is crucial, in frontline & salvage ‼️ Ph➕ ALL: Chemotherapy-free approach improves survival & spares transplant #leusm @DrHKantarjian @SocietyofHemOnc @OncoAlert

Expert recommendations on using MRD in #ALL now out in @BloodAdvances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT @MDAndersonNews #Leukemia doi.org/10.1182/bloodadvance… #leusm

RT @PeterHotez: Our ⁦@TXMedCenter⁩ before WWII and today (my photo from a Southwest Airlines flight). Today our Texas Medical Center in Hou…

‼️Only data so far of ICI in pts with cardiac Mets. Work led by @AminNassarMD @sarahaboualaiwi @TalalZarif1 out in @jitcancer . A collaboration that spanned several countries and centers. @OUCollegeofMed @StephensonCC @DrChoueiri jitc.bmj.com/content/13/3/e0…

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study out on JITC buff.ly/iFnRFbO This retrospective, multicenter study examined the safety and clinical outcomes of 110 patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs). The most common cancers were #melanoma (38%) and non-small cell lung cancer #NSCLC (24%), with cardiac metastases frequently located in the atria and ventricles. Cardiac events occurred in 36% of patients, but ICI-related major cardiac adverse events were rare (1.8%). Treatment-related adverse events (trAEs) were common, with 20% experiencing severe (grade ≥3) trAEs. Patients with multiple cardiac metastases had lower response rates to ICI-based therapies. Overall, ICIs showed meaningful efficacy, particularly in melanoma, with no increase in safety risks, highlighting the importance of multidisciplinary management in these complex cases. @AminNassarMD @sarahaboualaiwi @TalalZarif1 @RyanDenu @WNMacaron @Dory_Freeman @Avasbind @salimhayek @ShirlyGrynberg @jennkwanMDPhD @ProfGLongMIA @TarekHaykal1 @Atandondoc @nakhtermd @datsunian @EdwardElAmm @eliekozaily1 @ahmadalhader @boufarhat_elias @mer_herreraMD @chulkimMD @kaushalpar @ADesaiMD @ACortelliniMD @DJPinato @JamesKz_ @nerealiamd @FunchainMD @AChoudharyMD @AartiAsnaniMD @navstruck @ja_ocejo @JTrentMDPhD @DrRanaMcKay @TomasNeilan @DrChoueiri @thenasheffect

Our new paper in @jitcancer with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. jitc.bmj.com/content/13/3/e0… @thenasheffect @AminNassarMD @sarahaboualaiwi @TalalZarif1 @DrRanaMcKay @DanaFarber

CONGRESS #ASH24 | PRESENTATION @WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1. Poorer outcomes occurred in pts with HR B-ALL and slow MRD response. Follow our live feed for more updates: lymphoblastic-hub.com/medica… #ALL #ALLsm

Although immune checkpoint inhibitors demonstrate modest activity in cardiac soft tissue sarcomas, durable benefit was observed in a subset of patients w/ nonangiosarcoma, albeit w/ higher toxicity. bit.ly/3OvJiYD #JACCCardioOnc #CardioOnc #Immunotherapy @AminNassarMD

🫀Don't miss this original research from a great team in @JACCJournals! 📰tinyurl.com/bu4kxxnf @AminNassarMD @DrChoueiri @DrSarcoma @TomasNeilan @ADesaiMD @hannadallapria @RyanDenu #JACCCardioOnc

Adding gilteritinib to azacitidine and venetoclax shows improved outcomes in patients with FLT3-mutated acute myeloid leukemia, according to a study led by MD Anderson researchers. bit.ly/3SjKX4f @NicholasShortMD @DrHKantarjian @Daver_Leukemia @TapKadia #AML #EndCancer

Our paper on aza ven gilteritinib for FLT3mut #AML now online at @JCO_ASCO In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza ven) Could be delivered safely with appropriate dose modifications. ascopubs.org/doi/10.1200/JCO…

Aza ven gilteritinib highly effective in newly dx older FLT3-mut #AML: CR/CRi 96% and 18-month OS 72%. A new standard of care in this population. @NicholasShortMD of @MDAndersonNews #Leukemia ascopubs.org/doi/10.1200/JCO… @JCO_ASCO #leusm